Sat, Aug 23, 2014, 9:10 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Stryker Corporation Message Board

InvestorUSA 8 posts  |  Last Activity: Aug 7, 2014 2:28 PM Member since: Mar 30, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Start accumulating

    by comtraderman Aug 7, 2014 9:59 AM
    investorusa investorusa Aug 7, 2014 2:28 PM Flag

    MAKO senior management said the same thing regarding a buy-out... do not believe what you hear ... times change & circumstances will drive the returns/deal ... just let ISRG &/or SYK throw money their direction & watch what happens !!!!

  • investorusa by investorusa Aug 7, 2014 8:37 AM Flag

    We could use his wisdom/insight at this critical time for MZOR... he may have been one of the lucky ones & $old before the crash

  • investorusa by investorusa Jul 23, 2014 8:29 AM Flag

    BIG ? - How will the current fighting impact on MZOR ?????

    Sentiment: Strong Buy

  • Reply to

    Quality Assurance

    by investorusa Jul 17, 2014 12:13 PM
    investorusa investorusa Jul 17, 2014 12:47 PM Flag

    MZOR; NASDAQ GM: MZOR), a developer of innovative guidance systems and complementary products, announced results of data being presented July 16-19 at the 21st International Meeting on Advanced Spine Techniques (IMAST) meeting in Valencia, Spain.

    An e-poster entitled, Retrospective, Five-Center Analysis of 3,270 Pedicle Screws Placed with Robotic Guidance in Adolescent Idiopathic Scoliosis (AIS), reports that 223 patients with AIS in five centers, had a total of 3,270 pedicle screws placed using the Renaissance system with over 99 percent accuracy.

    A podium presentation, entitled, Retrospective Analysis of Feasibility and Performance of Robotic Guidance for Placement of Pedicle Screws in 223 Adolescents with Idiopathic Scoliosis (AIS), highlights that 3,270 screws were placed with the Renaissance system while fluoroscopy use was limited to 1.58 seconds per screw.

    “Anatomic constraints in AIS frequently confound placement of pedicle screws, especially when instrumenting the most deformed regions of a curved spine,” said Dr. Dennis P. Devito of Children’s Healthcare of Atlanta, one of the lead investigators of the study. “The accuracy of screw placement and reduced exposure to radiation per case results in safer operations for both the patient and surgical staff.”

    Other researchers involved in the study included:

    Dr. Isador Lieberman, Texas Back Institute, Plano, TX

    Dr. Samuel Bederman, UC Irvine Medical Center, Irvine, CA

    Dr. Raymond Woo, Florida Hospital for Children, Orlando, FL

    Dr. Sajan Hegde, Apollo Hospitals Chennai, Chennai, India

    Sentiment: Strong Buy

  • investorusa by investorusa Jul 17, 2014 12:13 PM Flag

    Data Presented at IMAST Shows Over 99 Percent Accuracy When Placing Screws with Mazor Robotics Renaissance Guidance System

    Sentiment: Strong Buy

  • Reply to

    UBS Conference Recap

    by donknute May 26, 2014 1:35 PM
    investorusa investorusa May 27, 2014 1:18 PM Flag

    The above confirms the growing list of reasons WHY MZOR is a superior investment opportunity to MAKO in my opinion

    THANKS for posting !!!!

    Sentiment: Strong Buy

  • Reply to

    Zacks opinion on VIVO...

    by investorusa May 23, 2014 3:09 PM
    investorusa investorusa May 23, 2014 3:34 PM Flag

    Gue$$ that I have placed a major bet that VIVO beats its OutLQQK !!!!! ;-)

  • investorusa by investorusa May 23, 2014 3:09 PM Flag

    For fiscal 2014, this Ohio-based fully integrated life sciences company saw six downward estimate revisions over the last one month with no upward revision. Consequently, the Zacks Consensus Estimate shrunk 9.3% to 88 cents per share for the year.

    Meridian Bioscience reported negative earnings surprises in 2 of the last 4 quarters, with an average miss of 2.1%.

    Shares of Meridian Bioscience recorded a drop of approximately 2.4% since reporting its fiscal 2014 second-quarter (ended Mar 31, 2014) results on Apr 24. Both earnings and revenues came in below expectations and management lowered its outlook for fiscal 2014.

    Earnings per share for the quarter were flat at 24 cents compared with the year-ago level and missed the Zacks Consensus Estimate by 3 cents. Revenues rose 6.1% year over year to $50.1 million but fell short of the Zacks Consensus Estimate of $52 million.

    Revenue growth was driven by an improvement in the company’s Life Science business. However, lower gross margins in this segment coupled with higher costs from the company’s Diagnostic business led to lower-than-anticipated operating margins during the quarter.

    Overall, results for the first half of fiscal 2014 remained weak as Meridian Bioscience witnessed soft food and respiratory sales, seasonal weakness and competitive pressures. For the first six months ended Mar 31, 2014, earnings per share fell 6.7% year over year to 42 cents.

    Meridian Bioscience’s hospital-associated infection (:HAI) category continues to lose momentum due to reduced rates of infection, lower hospital admissions and pricing pressure from increased competition.

    Reflecting the lackluster second-quarter results, Meridian Bioscience lowered its fiscal 2014 earnings per share guidance to a range of 0.85 to 0.90 cents from the prior range of 98 cents to $1.03. The Zacks Consensus Estimate of 87 cents lies within the guided range.

    Meridian Bioscience also slashed its fiscal 2014 revenue guidance to $190–$195 million fr

    Sentiment: Strong Buy

82.14-0.76(-0.92%)Aug 22 4:02 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.